Evercore, alongside Citi, has been enlisted as the financial advisor for Eli Lilly in its strategic acquisition of Morphic Holding, Inc., a deal poised to reshape treatment options for inflammatory bowel disease (IBD).
Valued at approximately $3.2 billion, this acquisition will see Lilly purchasing all outstanding shares of Morphic for $57 each, a significant premium over recent trading prices.
This move is approved by
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
Continue with Facebook Continue with Google